Home Newsfeeds Flemish Government And 3M Belgium Announce Plans For 3M Belgium To Invest €571M To ‘benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions.’

General

Flemish Government And 3M Belgium Announce Plans For 3M Belgium To Invest €571M To ‘benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions.’

ST. PAUL, Minn., July 6, 2022 /PRNewswire/ — Today, the Flemish Government and 3M Belgium announced plans for 3M Belgium to invest a total of more than €571 million to

byBill Haddad

July 6, 2022

1 minute read

ST. PAUL, Minn., July 6, 2022 /PRNewswire/ — Today, the Flemish Government and 3M Belgium announced plans for 3M Belgium to invest a total of more than €571 million to benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions. This agreement cooperatively resolves ongoing disagreements between the Flemish Government and 3M Belgium.

BrainStorm Cell Therapeutics Presents New Analyses From NurOwn’s Phase 3 ALS Trial At The 21st Annual NEALS Meeting

By Benzinga Newsdesk

November 7, 7:10 AM

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of a poster with new analyses from NurOwn's

BCLI

General

Jacobs And PA Consulting Deliver Sustainable Master Plan For Patrón Distillery

By Bill Haddad

September 20, 7:46 AM

DALLAS, Sept. 20, 2022 /PRNewswire/ -- Jacobs (NYSE:J) has completed master planning services for Hacienda Patrón tequila distillery in the state of Jalisco, Mexico. The

Reported Late Tuesday Feb. 28, Regeneron Pharmaceuticals And Sanofi Announce Kevzara Approved By FDA As First And Only Biologic Indicated For Patients With Polymyalgia Rheumatica

By Happy Mohamed

March 1, 1:25 AM

Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE,

REGN

Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-Related Deaths Marking These As Ninth Leading Cause Of Death In U.S.

By Benzinga Newsdesk

October 10, 8:10 AM

Salix Pharmaceuticals' Liver Health Annual Trends Report Findings Suggest Chronic Liver Disease (CLD) Deaths Could Triple Before the End of the DecadeBased Primarily on HCP-Market Research, Report Finds a Growing Concern

BHC

Flemish Government And 3M Belgium Announce Plans For 3M Belgium To Invest €571M To ‘benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions.’

Related Posts

BrainStorm Cell Therapeutics Presents New Analyses From NurOwn’s Phase 3 ALS Trial At The 21st Annual NEALS Meeting

Jacobs And PA Consulting Deliver Sustainable Master Plan For Patrón Distillery

Reported Late Tuesday Feb. 28, Regeneron Pharmaceuticals And Sanofi Announce Kevzara Approved By FDA As First And Only Biologic Indicated For Patients With Polymyalgia Rheumatica

Salix Pharmaceuticals Releases Liver Health Annual Trends Report Identifying Increase In Chronic Liver Disease And Cirrhosis-Related Deaths Marking These As Ninth Leading Cause Of Death In U.S.